Table 8.

The top 15 cited reviews related to the GM/CI.

Rank	Title	First author	Year	Journals	IF	Partition	TC
1	The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy	Havel, JJ.	2019	Nat. Rev. Cancer	60.716	Q1	956
2	The microbiota in adaptive immune homeostasis and disease	Honda, K.	2016	Nature	49.962	Q1	820
3	Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors	Pitt, JM.	2016	Immunity	31.745	Q1	538
4	The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy	Gopalakrishnan, V.	2018	Cancer Cell	31.743	Q1	459
5	Microbiota: a key orchestrator of cancer therapy	Roy, S.	2017	Nat. Rev. Cancer	60.716	Q1	414
6	Gut microbiota modulation of chemotherapy efficacy and toxicity	Alexander, JL.	2017	Nat. Rev. Gastroenterol. Hepatol.	46.802	Q1	359
7	The microbiome, cancer, and cancer therapy	Helmink, BA.	2019	Nat. Med.	53.44	Q1	341
8	The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies	Zitvogel, L.	2018	Science	47.728	Q1	308
9	Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors	Yi, M.	2018	Mol. Cancer	27.401	Q1	292
10	The hallmarks of successful anticancer immunotherapy	Galluzzi, L.	2018	Sci. Transl. Med.	17.992	Q1	267
11	The Role of the Microbiome in Cancer Development and Therapy	Bhatt, AP.	2017	CA-Cancer J. Clin.	508.702	Q1	244
12	Anticancer effects of the microbiome and its products	Zitvogel, L	2017	Nat Rev Microbiol.	60.633	Q1	218
13	The gut microbiota influences anticancer immunosurveillance and general health	Routy, B.	2018	Nat. Rev. Clin. Oncol.	66.675	Q1	211
14	Gut Microbiota and Cancer: From Pathogenesis to Therapy	Vivarelli, S.	2019	Cancers	6.639	Q1	203
15	Biomarkers for Clinical Benefit of immune Checkpoint inhibitor Treatment-A Review From the Melanoma Perspective and Beyond	Buder-Bakhaya K.	2018	Front. Immunol.	7.561	Q1	136